HUANGSHAN-TOURISM
Incorporated tourism contents from not only Mount Huangshan itself, but also with attractions in its neighborhood, the Grand Huangshan region made its debut at ITB Berlin 2024, the world’s leading travel trade show with over 5,500 exhibitors from 170 countries and regions, which concluded in Berlin on Thursday.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240307230072/en/
Famous scenery such as pine trees, cloud seas, peculiarly-shaped stone peaks of Mount Huangshan in East China's Anhui province. (Photo: Business Wire)
Located in East China's Anhui province, Mount Huangshan, also known as the Yellow Mountain, is famous for its pine trees, cloud seas, peculiarly-shaped stone peaks, hot springs and winter snow scenery. With its natural and cultural values well interconnected, Huangshan was inscribed on the UNESCO World Cultural and Natural Heritage List in 1990.
This year marks the fifth consecutive participation of Huangshan Tourism Co., Ltd. (HSTD) in the ITB. Compared to the conventionally produced booths of previous years, HSTD innovatively designed its booth with the theme of the world-class leisure and wellness tourism destination, the Grand Huangshan region, this time.
They incorporated elements from tourist attractions, intangible cultural heritage skills, and traditional Huizhou cuisine of the four core cities in the Grand Huangshan region: Huangshan, Anqing, Chizhou, and Xuancheng. The booth featured a backdrop of traditional Chinese landscape paintings, adorned with simplified drawings of Huizhou-style architectural features, presenting a fresh image to exhibitors and visitors from around the world.
Meanwhile, a series of introduction material like visitor's guide and creative designed souvenirs have been distributed during the event. And the Grand Huangshan regional tourism resources, Huizhou cultural characteristics and high-quality international tourist routes were introduced at ITB as well, inviting international guests.
Many visitors expressed that they looked forward to having the opportunity to visit Huangshan and will introduce the beautiful scenery of Huangshan to more people.
According to HSTD, it’s already the second splendid appearance on the international stage for Huangshan, after the London Trafalgar Square Chinese New Year Celebration event early in February. It is also a significant step in implementing Huangshan City's global promotion plan for the urban brand "Creative Huangshan, Beauty in Huizhou."
In recent years, Huangshan Tourism has been dedicated to international exchange, cooperation, and brand promotion. It has actively participated in internationally influential cultural and tourism exchange events such as the New York Asian Cultural Festival, the United Nations "Journey Through Civilizations" photo exhibition, and the New York "Chinese Night."
Simultaneously, there has been a continuous increase in efforts to promote the brand worldwide, showcasing the tourism resources and cultural heritage of the beautiful Huangshan to overseas residents and tourists through multi-dimensional, comprehensive, and close-range approaches.
According to Huangshan, it will continue to spare no effort in showcasing the image of the Huangshan to international tourists in a fresh and compelling way and enhancing the visibility and influence of Grand Huangshan region as an international famous tourism destination.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240307230072/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press release
Announcement of Enry’s Island AdVentures: the world’s first video game to learn how to launch and scale startups, focused on democratizing innovation for “Long Tail Users” Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press release
Part of the Digital Morocco 2030 strategy, 500 Global has been selected to support the Startup Venture Building (Startup VB) initiative. 500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to streng
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press release
New capital accelerates Neural Concept’s ability to deliver transformative technologies and enterprise-wide AI impact across advanced industrial workflows.Platform delivers CAD-native, physics-aware AI and deep reasoning for engineering, saving customers $50 million annually, reducing late-stage redesigns by 30-50% and accelerating time to market by up to two years.The company has generated a fourfold increase in enterprise revenue over the past 18 months.More than 50 global companies are actively relying on the platform, including General Motors, General Electric Vernova, Leonardo Aerospace, Eaton, Safran, Renault Group and multiple Formula 1 teams. Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special?MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
